false
0001267565
0001267565
2024-06-13
2024-06-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 13, 2024
COLLEGIUM PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
| Virginia |
|
001-37372 |
|
03-0416362 |
(State or Other
Jurisdiction
of Incorporation or Organization) |
|
(Commission File Number) |
|
(IRS Employer Identification
No.) |
| 100 Technology Center Drive |
| Suite 300 |
| Stoughton, MA 02072 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including
area code: (781) 713-3699
Securities registered pursuant to Section 12(b) of the Act:
| Title of
each class |
Trading Symbol(s) |
Name of each
exchange on which registered |
| Common stock, par value $0.001 per share |
COLL |
The NASDAQ Global Select Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 |
Other Information. |
On June 13, 2024, Collegium Pharmaceutical, Inc. issued a
press release announcing the U.S. Food and Drug Administration (“FDA”) has granted pediatric exclusivity for Nucynta®
and Nucynta® ER (“the Nucynta Franchise”), extending exclusivity of the Nucynta Franchise an additional six months, to
January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
| Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 13, 2024 |
Collegium Pharmaceutical, Inc. |
| |
|
|
| |
By: |
/s/ Colleen Tupper |
| |
|
Name: Colleen Tupper |
| |
|
Title: Executive Vice President and Chief Financial Officer |
Exhibit 99.1
Collegium Obtains Six Month Extension of U.S.
Pediatric Exclusivity for Nucynta Franchise
STOUGHTON, Mass., June 13, 2024
-- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to
improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA)
has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In
2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27,
2025, to July 3, 2026. FDA’s grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional
six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER.
“We are pleased with FDA’s grant of pediatric exclusivity
for the Nucynta Franchise,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “This grant of pediatric exclusivity
enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of
people living with serious medical conditions and the communities we serve.”
Nucynta is currently approved in the U.S. for the management of acute
pain severe enough to require an opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative
treatments are inadequate in adults and pediatric patients aged six years and older with a body weight of at least 40 kg.
Nucynta ER is currently approved in the U.S. for the management of
severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic, in light of the known risks
associated with opioid analgesic use, and for which alternative treatment options are inadequate, and severe and persistent neuropathic
pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic
and for which alternative treatment options are inadequate.
Please see Important Safety Information
that follows below and complete product information, including the Boxed Warning, available at www.NUCYNTA.com.
About Collegium Pharmaceutical, Inc.
Collegium is a leading, diversified specialty
pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters
are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
NUCYNTA® (tapentadol) INDICATIONS AND USAGE
NUCYNTA® (tapentadol) tablets are:
| · | A strong prescription pain medicine that contains an opioid (narcotic) that
is used to manage short term (acute) pain in adults and children 6 years of age and older who weigh at least 88 pounds (40 kg), when other
pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them. |
| · | An opioid pain medicine that can put you at risk for overdose and death.
Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death. |
IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA TABLETS
|
WARNING: SERIOUS AND LIFE-THREATENING RISKS
FROM USE OF NUCYNTA TABLETS
Addiction, Abuse, and Misuse
Because the use of NUCYNTA tablets exposes patients and other users
to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing
and reassess regularly for the development of these behaviors and conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur
with use of NUCYNTA tablets, especially during initiation of NUCYNTA tablets or following a dose increase. To reduce the risk of respiratory
depression, proper dosing and titration of NUCYNTA tablets are essential.
Accidental Ingestion
Accidental ingestion of even one dose of NUCYNTA tablets, especially
by children, can result in a fatal overdose of tapentadol.
Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central
nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve
concomitant prescribing of NUCYNTA tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment
options are inadequate.
Neonatal Opioid Withdrawal Syndrome
If opioid use is required for an extended period of time in a pregnant
woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life threatening if not recognized and treated.
Ensure that management by neonatology experts will be available at delivery.
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant
education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide
with each prescription.
|
Important information about NUCYNTA tablets:
| · | Get emergency help or call 911 right away if you take too much NUCYNTA
(overdose) tablets. When you first start taking NUCYNTA tablets, when your dose is changed, or if you take too much (overdose), serious
or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for
the emergency treatment of an opioid overdose. |
| · | Taking NUCYNTA tablets with other opioid medicines, benzodiazepines, alcohol,
or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems,
coma, and death. |
| · | Never give anyone else your NUCYNTA tablets. They could die from taking it.
Selling or giving away NUCYNTA tablets is against the law. |
| · | Store NUCYNTA tablets securely, out of sight and reach of children, and in
a location not accessible by others, including visitors to the home. |
Do not take NUCYNTA tablets if you have:
| · | severe asthma, trouble breathing, or other lung problems. |
| · | a bowel blockage or have narrowing of the stomach or intestines. |
Before taking NUCYNTA tablets, tell your healthcare provider if
you have a history of:
| · | abuse of street or prescription drugs, alcohol addiction, opioid overdose
or mental health problems |
| · | liver, kidney, thyroid problems |
| · | pancreas or gallbladder problems |
Tell your healthcare provider if you:
| · | notice your pain getting worse. If your pain gets worse after you
take NUCYNTA tablets, do not take more NUCYNTA tablets without first talking to your healthcare provider. Tell your healthcare provider
if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA tablets. |
| · | are pregnant or planning to become pregnant. Use of NUCYNTA tablets
for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not
recognized and treated. |
| · | are breastfeeding. NUCYNTA tablets pass into breast milk and may harm
your baby. |
| · | are living in a household where there are small children or someone who has
abused street or prescription drugs. |
| · | are taking prescription or over-the-counter medicines, vitamins, or herbal
supplements. Taking NUCYNTA tablets with certain other medicines can cause serious side effects that could lead to death. |
When taking NUCYNTA tablets:
| · | Do not change your dose. Take NUCYNTA tablets exactly as prescribed by your
healthcare provider. |
| · | Use the lowest dose possible for the shortest time needed. |
| · | For acute (short-term) pain, you may only need to take NUCYNTA tablets for
a few days. You may have some NUCYNTA tablets left over that you did not use. See disposal information at the bottom of this section for
directions on how to safely throw away (dispose of) your unused NUCYNTA tablets. |
| · | Take your prescribed dose every 4-6 hours, at the same time every day. Do
not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time. |
| · | Call your healthcare provider if the dose you are taking does not control
your pain. |
| · | If you have been taking NUCYNTA tablets regularly, do not stop taking NUCYNTA
tablets without talking to your healthcare provider. |
| · | Dispose of expired, unwanted, or unused NUCYNTA Tablets by promptly flushing
down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal
of unused medicines. |
While taking NUCYNTA tablets, DO NOT:
| · | Drive or operate heavy machinery, until you know how NUCYNTA tablets affect
you. NUCYNTA tablets can make you sleepy, dizzy, or lightheaded. |
| · | Drink alcohol or use prescription or over-the-counter medicines that contain
alcohol. Using products containing alcohol during treatment with NUCYNTA tablets may cause you to overdose and die. |
The possible side effects of NUCYNTA tablets:
| · | constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness,
abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe. |
Get emergency medical help or call 911 right away if you have:
| · | trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling
of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature,
trouble walking, stiff muscles, or mental changes such as confusion. |
These are not all of the possible side
effects of NUCYNTA tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
For more information, go to dailymed.nlm.nih.gov.
See full Prescribing Information,
including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at
Nucynta.com/IRpi. Speak to your healthcare provider if you have questions about Nucynta.
NUCYNTA® ER (tapentadol) INDICATIONS AND USAGE
NUCYNTA® ER (tapentadol) extended-release tablets
are:
| · | A strong prescription pain medicine that contains an opioid (narcotic) that
is used to manage severe and persistent pain in adults that requires an extended treatment period with a daily opioid pain medicine, when
other pain medicines do not treat your pain well enough or you cannot tolerate them. |
| · | Also used in adults to manage severe and persistent pain from damaged nerves
(neuropathic pain) that happens with diabetes, and that requires an extended treatment period with a daily opioid pain medicine, when
other pain medicines do not treat your pain well enough or you cannot tolerate them. |
| · | A long-acting (extended-release) opioid pain medicine that can put you at
risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse
that can lead to death. |
| · | Not to be taken on an “as needed” basis. |
IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA ER
|
WARNING: SERIOUS AND LIFE-THREATENING RISKS
FROM USE OF NUCYNTA ER
Addiction, Abuse, and Misuse
Because the use of NUCYNTA ER exposes patients and other users to
the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing
and reassess all patients regularly for the development of these behaviors and conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur
with use of NUCYNTA ER, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper
dosing and titration of NUCYNTA ER are essential. Instruct patients to swallow NUCYNTA ER tablets whole; crushing, chewing, or dissolving
NUCYNTA ER tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol.
Accidental Ingestion
Accidental ingestion of even one dose of NUCYNTA ER, especially
by children, can result in a fatal overdose of tapentadol. Interaction With Alcohol Instruct patients not to consume alcoholic beverages
or use prescription or non-prescription products that contain alcohol while taking NUCYNTA ER. The co-ingestion of alcohol with NUCYNTA
ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol.
Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central
nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve
concomitant prescribing of NUCYNTA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment
options are inadequate.
Neonatal Opioid Withdrawal Syndrome (NOWS)
If opioid use is required for an extended period of time in a pregnant
woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by
neonatology experts will be available at delivery.
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant
education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide
with each prescription.
|
Important information about NUCYNTA ER:
| · | Get emergency help or call 911 right away if you take too much NUCYNTA
ER (overdose). When you first start taking NUCYNTA ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening
breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment
of an opioid overdose. |
| · | Taking NUCYNTA ER with other opioid medicines, benzodiazepines, alcohol,
or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems,
coma, and death. |
| · | Never give anyone else your NUCYNTA ER. They could die from taking it. Selling
or giving away NUCYNTA ER is against the law. |
| · | Store NUCYNTA ER securely, out of sight and reach of children, and in a location
not accessible by others, including visitors to the home. |
Do not take NUCYNTA ER if you have:
| · | severe asthma, trouble breathing, or other lung problems. |
| · | a bowel blockage or have narrowing of the stomach or intestines. |
Before taking NUCYNTA ER, tell your healthcare provider if you have
a history of:
| · | abuse of street or prescription drugs, alcohol addiction, opioid overdose
or mental health problems |
| · | liver, kidney, thyroid problems |
| · | pancreas or gallbladder problems |
Tell your healthcare provider if you:
| · | notice your pain getting worse. If your pain gets worse after you take NUCYNTA
ER, do not take more of NUCYNTA ER without first talking to your healthcare provider. Talk to your healthcare provider if the pain that
you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA ER. |
| · | are pregnant or planning to become pregnant. Use of NUCYNTA ER for
an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized
and treated. |
| · | are breastfeeding. Not recommended during treatment with NUCYNTA ER.
It may harm your baby. |
| · | are living in a household where there are small children or someone who has
abused street or prescription drugs. |
| · | are taking prescription or over-the-counter medicines, vitamins, or herbal
supplements. Taking NUCYNTA ER with certain other medicines can cause serious side effects. |
When taking NUCYNTA ER:
| · | Do not change your dose. Take NUCYNTA ER exactly as prescribed by your healthcare
provider. Use the lowest effective dose for the shortest time needed. |
| · | Take your prescribed dose every 12 hours, at the same time every day. Do
not take more than your prescribed dose in 24 hours. If you miss a dose, take your next dose at your usual time. |
| · | Swallow NUCYNTA ER whole. Do not cut, break, chew, crush, dissolve, snort,
or inject NUCYNTA ER because this may cause you to overdose and die. |
| · | Call your healthcare provider if the dose you are taking does not control
your pain. |
| · | Do not stop taking NUCYNTA ER without talking to your healthcare provider. |
| · | Dispose of expired, unwanted, or unused NUCYNTA ER by promptly flushing down
the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal
of unused medicines. |
While taking NUCYNTA ER, DO NOT:
| · | Drive or operate heavy machinery until you know how NUCYNTA ER affects you.
NUCYNTA ER can make you sleepy, dizzy, or lightheaded. |
| · | Drink alcohol or use prescription or over-the-counter medicines containing
alcohol. Using products containing alcohol during treatment with NUCYNTA ER may cause you to overdose and die. |
The possible side effects of NUCYNTA ER are:
| · | constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness,
abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe. |
Get emergency medical help or call 911 right away if you have:
| · | trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling
of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature,
trouble walking, stiff muscles, or mental changes such as confusion. |
| · | agitation, hallucinations, coma, feeling overheated, or heavy sweating. |
These are not all the possible side effects
of NUCYNTA ER. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
For more information go to dailymed.nlm.nih.gov.
See full Prescribing Information,
including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, accompanying this piece or at Nucynta.com/ERpi.
Speak to your healthcare provider if you have questions about Nucynta ER.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts,"
"believes," "potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "should"
or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking
statements contained in this press release include, among others, statements related to current and future market opportunities for our
products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not
historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results,
performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others:
unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial
performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with
licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products,
and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and
our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and
degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing
market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the
outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient
for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations
and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient
intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the
manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the
accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are
described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and
other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise,
after the date of this press release.
Investor Contact:
Christopher James, M.D.
Vice President, Investor Relations
ir@collegiumpharma.com
Media Contact:
Marissa Samuels
Vice President, Corporate Communications
communications@collegiumpharma.com
v3.24.1.1.u2
Cover
|
Jun. 13, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Jun. 13, 2024
|
| Entity File Number |
001-37372
|
| Entity Registrant Name |
COLLEGIUM PHARMACEUTICAL, INC.
|
| Entity Central Index Key |
0001267565
|
| Entity Tax Identification Number |
03-0416362
|
| Entity Incorporation, State or Country Code |
VA
|
| Entity Address, Address Line One |
100 Technology Center Drive
|
| Entity Address, Address Line Two |
Suite 300
|
| Entity Address, City or Town |
Stoughton
|
| Entity Address, State or Province |
MA
|
| Entity Address, Postal Zip Code |
02072
|
| City Area Code |
781
|
| Local Phone Number |
713-3699
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common stock, par value $0.001 per share
|
| Trading Symbol |
COLL
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Collegium Pharmaceutical (NASDAQ:COLL)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Collegium Pharmaceutical (NASDAQ:COLL)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
